MedTrace Logo

Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

NCT04362462 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-04-27

No results posted yet for this study

Summary

Neoadjuvant chemotherapy (NACT) can induce complete pathologic response (pCR) in approximately 35-55% of patient with triple-negative breast cancer (TNBC). These patients have excellent long term survivals. On the other hand patients with residual disease exhibit a high rate of local or metastatic. Although it has been successful in some regards, randomized trials have shown similar rates of mortality between patients receiving NACT and adjuvant chemotherapy (ACT). The goal of this study is to understand the molecular biology (gene expression signature) driving treatment-resistant TNBC. The investigators are planning to identify targetable genetic alterations which may help to optimize adjuvant therapy for the patient with residual TNBC.

Conditions

  • Triple-negative Breast Cancer

Sponsors & Collaborators

  • Texas Tech University Health Sciences Center, El Paso

    lead OTHER

Principal Investigators

  • Alexander Philipovskiy, MD, PhD · Texas Tech University Health Sciences Center, El Paso

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04362462 on ClinicalTrials.gov